BXL628, A Novel Vitamin D3 Analog Arrests Prostate Growth in Patients with Benign Prostatic Hyperplasia: A Randomized Clinical Trial

Weiner, 1997, Urologic manpower issues for the 21st century: assessing the impact of changing population dynamics, Urology, 49, 335, 10.1016/S0090-4295(96)00492-X Williams, 1999, Prostatic growth rate determined from MRI data: age-related longitudinal changes, J Androl, 20, 474 Anderson, 2001, The progression of benign prostatic hyperplasia: examining the evidence and determining the risk, Eur Urol, 39, 390, 10.1159/000052475 Chapple, 2004, Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician, BJU Int, 94, 1399 Foley, 2004, An update on the use of 5alpha-reductase inhibitors, Drug Today (Barc), 40, 213, 10.1358/dot.2004.40.3.820085 McConnell, 2003, The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia, N Engl J Med, 349, 2387, 10.1056/NEJMoa030656 Carbone, 2003, Medical therapy for benign prostatic hyperplasia: sexual dysfunction and impact on quality of life, Int J Impot Res, 15, 299, 10.1038/sj.ijir.3901017 Peehl, 1994, Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells, Cancer Res, 54, 805 Kivineva, 1998, Localization of 1,25-dihydroxyvitamin D3 receptor (VDR) expression in human prostate, J Steroid Biochem Mol Biol, 66, 121, 10.1016/S0960-0760(98)00054-5 Crescioli, 2000, Effect of a vitamin D3 analogue on keratinocyte growth factor-induced cell proliferation in benign prostate hyperplasia, J Clin Endocrinol Metab, 85, 2576 Tong, 2000, Therapeutic effects in postmenopausal, osteoporotic (PMOP) women of a vitamin D analog, Ro-26-9228, with minimal effects on calcium (Ca) homeostatis, J Bone Miner Res, 15, S562 Crescioli, 2004, Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia, Eur J Endocrinol, 150, 591, 10.1530/eje.0.1500591 Hricak, 1987, Evaluation of prostate size: comparison of ultrasound and magnetic resonance imaging, Urol Radiol, 9, 1, 10.1007/BF02932619 Rahmouni, 1992, Accuracy of in-vivo assessment of prostatic volume by MRI and transrectal ultrasonography, J Comput Assist Tomogr, 16, 935, 10.1097/00004728-199211000-00020 Aaenink, 1996, Formula-derived prostate volume determination, Eur Urol, 29, 399, 10.1159/000473786 McConnell, 1998, The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia, N Engl J Med, 338, 557, 10.1056/NEJM199802263380901 Stoner, 1992, The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The finasteride Study Group, J Urol, 147, 1298, 10.1016/S0022-5347(17)37547-X